{"id":"valsartan-simvastatin","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Valsartan works by blocking the angiotensin II receptor, which is part of the renin-angiotensin-aldosterone system (RAAS) that regulates blood pressure. By blocking this receptor, valsartan causes vasodilation and reduces blood pressure. Simvastatin, on the other hand, works by inhibiting HMG-CoA reductase, a key enzyme in the cholesterol synthesis pathway. This inhibition reduces the production of cholesterol in the liver, thereby lowering cholesterol levels in the blood.","oneSentence":"Valsartan is an angiotensin II receptor antagonist that blocks the effects of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:32.598Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Hyperlipidemia"}]},"trialDetails":[{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT00385931","phase":"PHASE3","title":"Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin","status":"COMPLETED","sponsor":"Novartis","startDate":"2002-01","conditions":"Hypertension, Hypercholesterolemia, Dyslipidemia","enrollment":412},{"nctId":"NCT04859452","phase":"PHASE1","title":"A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2021-05-26","conditions":"Healthy Subjects","enrollment":56},{"nctId":"NCT04061824","phase":"PHASE4","title":"Clinical Study to Evaluate Adherence Improvement Fixed-dose Combination of Olostar Tab. in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-05-24","conditions":"Hypertension, Dyslipidemias","enrollment":150},{"nctId":"NCT00171093","phase":"PHASE3","title":"A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Novartis","startDate":"2004-09","conditions":"HYPERTENSION, HYPERCHOLESTEROLEMIA","enrollment":369},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00839683","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study of Dapagliflozin and Valsartan or Simvastatin in Healthy Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-02","conditions":"Type 2 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00254475","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia","status":"COMPLETED","sponsor":"Novartis","startDate":"2005-11","conditions":"Essential Hypertension, Hypercholesterolemia","enrollment":871},{"nctId":"NCT00738972","phase":"PHASE3","title":"Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)","status":"TERMINATED","sponsor":"Fundación Lindavista del Corazón AC","startDate":"2008-01","conditions":"Hypertension","enrollment":12},{"nctId":"NCT00664846","phase":"NA","title":"Standard Medical Management in Secondary Prevention of Ischemic Stroke in China","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2008-04","conditions":"Stroke","enrollment":4000},{"nctId":"NCT00691314","phase":"NA","title":"Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2008-06","conditions":"Stroke, Transient Ischemic Attack, Atherosclerosis","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"valsartan + simvastatin","genericName":"valsartan + simvastatin","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Valsartan is an angiotensin II receptor antagonist that blocks the effects of angiotensin II, a potent vasoconstrictor, thereby lowering blood pressure. Simvastatin is a statin that inhibits HMG-CoA reductase, a key enzyme in cholesterol synthesis, thereby lowering cholesterol levels. Used for Hypertension, Hyperlipidemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}